eMedicine Specialties > Emergency Medicine > Warfare - Chemical, Biological, Radiological, Nuclear and Explosives

CBRNE - Incapacitating Agents, Agent 15

Author: Geoffrey M Fitzgerald, MD, Consulting Staff, Concord Emergency Medical Associates
Coauthor(s): David P Sole, DO, FACEP, Associate Director of Emergency Medical Service Programs, Clinical Assistant Professor of Surgery (Emergency Medicine), Department of Emergency Medicine & Residency Program, Geisinger Medical Center
Contributor Information and Disclosures

Updated: Apr 10, 2009

Introduction

Background

"Incapacitating agent" is a military term used to denote an agent that temporarily and nonlethally impairs the performance of an enemy by targeting the central nervous system (CNS). Of those substances investigated by the military, anticholinergic agents best fit these criteria and are stable enough for use in war. As far back as 184 BC, Hannibal's army used belladonna plants to induce disorientation in enemies. In 1672, the Bishop of Muenster used belladonna-containing grenades in his campaigns.

Approximately 300 years later, the US Army explored several classes of drugs, as well as noise, microwaves, and photostimulation, and found none to be as promising incapacitating agents as the anticholinergics. Stimulants such as cocaine, amphetamines, and nicotine were tested but did not have the potency to be an airborne threat. Depressants (eg, barbiturates, opiates, neuroleptics) similarly were found to be impractical for battlefield use. The unpredictable behavior incurred by psychedelic agents (ie, lysergic acid diethylamide [LSD], phencyclidine [PCP]) led to an early halt in the testing of that particular class of drugs.

By the mid-1960s, after a decade of tests, the US Army concluded that the long-acting anticholinergic 3-quinuclidinyl benzilate (BZ) was the best candidate for weaponization and deployment. BZ subsequently was stockpiled in American military arsenals from the mid-1960s through the late-1980s. The US military was not alone in its attempt to develop an incapacitating agent in the 20th century. Seven years after the conclusion of the Gulf War, the British Foreign Ministry revealed, in February 1998, the existence of an Iraqi chemical warfare agent believed to be a glycolate anticholinergic, similar, if not identical, to BZ. It was dubbed "Agent 15." Little information is known publicly about Agent 15. For this reason, also refer to CBRNE - Incapacitating Agents, 3-Quinuclidinyl Benzilate .

Pathophysiology

BZ is the North Atlantic Treaty Organization (NATO) code for 3-quinuclidinyl benzilate, a glycolate anticholinergic also known as 3-QNB. Both BZ and its Iraqi look-alike, Agent 15, are competitive inhibitors of the effects of acetylcholine at the postsynaptic muscarinic receptors in the peripheral and central nervous systems. In the peripheral nervous system, this inhibition is observed in the smooth muscle, autonomic ganglia, and exocrine glands. BZ's ability to readily cross the blood-brain barrier allows it to wreak havoc on the CNS, causing mental status changes and delirium.

A common problem in developing a chemical warfare agent is finding an effective and reliable chemical. The glycolate anticholinergics (eg, BZ, Agent 15) fit this description. Extremely stable, these chemicals have a half-life of 3-4 weeks in moist air and even longer on surfaces or in soil. Absorption of glycolates can occur following inhalation, ingestion, or cutaneous exposure. Only small doses of this potent drug are needed to produce delirium. The dose of BZ needed to incapacitate 50% of those exposed is 6.2 mcg/kg, compared to 140 mcg/kg for atropine.

Frequency

United States

With the exception of Army test volunteers in the 1960s, anticholinergic incapacitating agents have not been used in the US. Although many experts believe that most terrorists would opt for a lethal form of chemical attack (eg, nerve agent), use of incapacitating agents cannot be discounted. Other sources of anticholinergic toxicity include clinical medicines such as atropine, antihistamines, and tricyclic antidepressants.

Numerous plants commonly found in North America also can cause delirium indistinct from exposure to an incapacitating agent. Examples include jimsonweed, nightshade, belladonna, and other members of the Solanaceae family.

International

Iraq is known to possess Agent 15. Other governments accused of possibly possessing incapacitating agents include the former Soviet Union and Bosnia.

Mortality/Morbidity

By definition, incapacitating agents are nonlethal. BZ has a high safety ratio. The dose required to produce incapacitating effects is roughly 40 times less than the fatal dose. Fatalities from this class of drug can result from hyperthermia or from the casualty's delirious behavior. Such a scenario was dramatized in the 1990s movie "Jacob's Ladder," in which a fictitious military unit kills itself after accidental exposure to an incapacitant-type chemical warfare agent.

Clinical

History

  • The patient may complain of dry mouth, a hot feeling, or blurred vision.
  • Changes in mental status produced by incapacitating agents may leave some patients delirious to the point that they fail to or are unable to report symptoms.

Physical

Remarkably little variation exists among individuals when anticholinergics are administered.

  • Following exposure, typically a latent period of 30 minutes to 24 hours occurs before signs and symptoms appear.
  • Anticholinergic toxicity caused by BZ or Agent 15 can last up to 3-4 days, depending on the amount of drug absorbed.
  • Peripheral effects usually precede CNS effects and can be summarized by the mnemonic "dry as a bone, hot as Hades, red as a beet, and blind as a bat."
    • "Dry as a bone" results from decreased glandular secretions in the oral pharynx, GI tract, and eccrine and apocrine glands. Urinary retention also is common.
    • "Hot as Hades" refers to hyperthermia caused by decreased sweating.
    • The body attempts to maintain thermoregulation via compensatory cutaneous vasodilatation, hence "red as a beet."
    • Decreased cholinergic stimulation of the pupillary sphincter muscle causes mydriasis. Anticholinergic effects on the ciliary muscles inhibit accommodation, hence "blind as a bat."
    • Anticholinergic effects on the heart produce tachycardia. This occasionally is preceded by a bradycardia that results from anticholinergic effects in the brain stem.
  • The CNS effects of BZ and Agent 15 make them effective incapacitants.
    • Patients receiving these agents react with mental status changes ("mad as a hatter") in a dose-dependent fashion.
    • After a latent period and following the appearance of the peripheral effects, the casualty's mental status begins to fluctuate between a relatively conscious state and frank delirium.
    • Level of consciousness can range from drowsiness to coma.
    • Disorientation to time and place, decreased social restraint with inappropriate behavior, and decreased short-term memory are common.
    • Speech becomes slurred and indistinct.
    • Poor coordination leads to ataxia and agraphia.
    • Anticholinergic toxicity can produce vivid and realistic hallucinations that tend to decrease in size over time. For example, a polar bear may be replaced by a smaller animal such as a rabbit as the toxidrome clears.
    • When multiple victims of anticholinergic toxicity interact, they may play off each other's delirium. An example is 2 victims playing tennis with imaginary racquets. Another term for this shared hallucination is "folie a deux."
    • Phantom behaviors such as plucking or picking at one's clothes (ie, wool gathering) often were observed in Army test subjects who received BZ.
    • As the BZ victim's delirium clears, paranoid tendencies are not uncommon.
  • Of final note on the examination is an increase in deep tendon reflexes. Anticholinergic effects on the Renshaw interneurons in the spinal cord cause hyperreflexia.

Causes

  • Consider any cause of delirium. Psychiatric disorders such as anxiety reaction also are in the differential diagnosis.
  • The presence of peripheral anticholinergic signs suggests another source of anticholinergic such as scopolamine,1 atropine, jimsonweed, or other anticholinergic source exposure.
  • Usually, 6-7 MARK-1 Autoinjectors (ie, 12-14 mg of IM atropine) are needed to cause a significant degree of confusion.
  • Nerve agent poisoning can be differentiated by its hyperstimulation of glands.

More on CBRNE - Incapacitating Agents, Agent 15

Overview: CBRNE - Incapacitating Agents, Agent 15
Differential Diagnoses & Workup: CBRNE - Incapacitating Agents, Agent 15
Treatment & Medication: CBRNE - Incapacitating Agents, Agent 15
Follow-up: CBRNE - Incapacitating Agents, Agent 15
References

References

  1. Goldfrank L, Flomenbaum N, Lewin N, et al. Anticholinergic poisoning. J Toxicol Clin Toxicol. Mar 1982;19(1):17-25. [Medline].

  2. Bowen TE. Emergency War Surgery. Revisionist Press; 1988:93-94.

  3. Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. Apr 2000;35(4):374-81. [Medline].

  4. Goldfrank LR, Flomenbaum NE. Goldfrank's Toxicologic Emergencies. Appleton & Lange; 1998.

  5. Ketchum JS, Sidell FR. Incapacitating agents. In: Textbook of Military Medicine, Warfare, Weaponry and the Casualty: Medical Aspects of Chemical and Biological Warfare. United States Government Printing Office; 1997:287-306.

  6. Schneir AB, Offerman SR, Ly BT, Davis JM, Baldwin RT, Williams SR, et al. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med. Jul 2003;42(1):14-9. [Medline].

  7. Shannon M. Toxicology reviews: physostigmine. Pediatr Emerg Care. Jun 1998;14(3):224-6. [Medline].

  8. Tintinalli JE. Anticholinergic toxicity. In: Emergency Medicine: A Comprehensive Study Guide. McGraw Hill; 2000:1182-1185.

Further Reading

Keywords

chemical weapon, chemical warfare, anticholinergic, glycolates, delirium, agent 15, incapacitating agents, anticholinergic agents, anticholinergic 3-quinuclidinyl benzilate, BZ, 3-quinuclidinyl benzilate, glycolate anticholinergic, 3-QNB, chemical warfare agent

Contributor Information and Disclosures

Author

Geoffrey M Fitzgerald, MD, Consulting Staff, Concord Emergency Medical Associates
Disclosure: Nothing to disclose.

Coauthor(s)

David P Sole, DO, FACEP, Associate Director of Emergency Medical Service Programs, Clinical Assistant Professor of Surgery (Emergency Medicine), Department of Emergency Medicine & Residency Program, Geisinger Medical Center
David P Sole, DO, FACEP is a member of the following medical societies: American College of Emergency Physicians and National Association of EMS Physicians
Disclosure: Nothing to disclose.

Medical Editor

Suzanne White, MD, Medical Director, Regional Poison Control Center at Children's Hospital, Program Director of Medical Toxicology, Associate Professor, Departments of Emergency Medicine and Pediatrics, Wayne State University School of Medicine
Suzanne White, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Clinical Toxicology, American College of Epidemiology, American College of Medical Toxicology, American Medical Association, and Michigan State Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Robert G Darling, MD, FACEP, Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine
Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, and Association of Military Surgeons of the US
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.